Your browser doesn't support javascript.
loading
Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.
Choi, Jun Yong; Fuerst, Rita; Knapinska, Anna M; Taylor, Alexander B; Smith, Lyndsay; Cao, Xiaohang; Hart, P John; Fields, Gregg B; Roush, William R.
Afiliação
  • Choi JY; Department of Chemistry, Scripps Florida , 130 Scripps Way, Jupiter, Florida 33458, United States.
  • Fuerst R; Department of Chemistry, Scripps Florida , 130 Scripps Way, Jupiter, Florida 33458, United States.
  • Knapinska AM; Department of Chemistry & Biochemistry, Florida Atlantic University , Jupiter, Florida 33458, United States.
  • Taylor AB; Department of Biochemistry and Structural Biology and the X-ray Crystallography Core Laboratory, University of Texas Health Science Center at San Antonio , San Antonio, Texas 78229, United States.
  • Smith L; Department of Chemistry & Biochemistry, Florida Atlantic University , Jupiter, Florida 33458, United States.
  • Cao X; Department of Biochemistry and Structural Biology and the X-ray Crystallography Core Laboratory, University of Texas Health Science Center at San Antonio , San Antonio, Texas 78229, United States.
  • Hart PJ; Department of Biochemistry and Structural Biology and the X-ray Crystallography Core Laboratory, University of Texas Health Science Center at San Antonio , San Antonio, Texas 78229, United States.
  • Fields GB; Department of Chemistry & Biochemistry, Florida Atlantic University , Jupiter, Florida 33458, United States.
  • Roush WR; Department of Chemistry, Scripps Florida , 130 Scripps Way, Jupiter, Florida 33458, United States.
J Med Chem ; 60(13): 5816-5825, 2017 07 13.
Article em En | MEDLINE | ID: mdl-28653849
We describe the use of comparative structural analysis and structure-guided molecular design to develop potent and selective inhibitors (10d and (S)-17b) of matrix metalloproteinase 13 (MMP-13). We applied a three-step process, starting with a comparative analysis of the X-ray crystallographic structure of compound 5 in complex with MMP-13 with published structures of known MMP-13·inhibitor complexes followed by molecular design and synthesis of potent but nonselective zinc-chelating MMP inhibitors (e.g., 10a and 10b). After demonstrating that the pharmacophores of the chelating inhibitors (S)-10a, (R)-10a, and 10b were binding within the MMP-13 active site, the Zn2+ chelating unit was replaced with nonchelating polar residues that bridged over the Zn2+ binding site and reached into a solvent accessible area. After two rounds of structural optimization, these design approaches led to small molecule MMP-13 inhibitors 10d and (S)-17b, which bind within the substrate-binding site of MMP-13 and surround the catalytically active Zn2+ ion without chelating to the metal. These compounds exhibit at least 500-fold selectivity versus other MMPs.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Metaloproteinase 13 da Matriz / Inibidores de Metaloproteinases de Matriz Limite: Humans Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Metaloproteinase 13 da Matriz / Inibidores de Metaloproteinases de Matriz Limite: Humans Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos